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Introduction
Chronic recurrent multifocal osteomyelitis (CRMO) is
an inflammatory disorder of unknown etiology, charac-
terized by nonbacterial inflammatory bone lesions. The
bone lesions can be unifocal or multifocal, and have an
either uniphasic or recurrent course.
Non-steroidal anti-inflammatory drugs (NSAIDs) and
Glucocorticoid have been reported to be effective in
some cases, and more recently tumor necrosis factor-
alpha (TNF-a) inhibitors have shown effect in more
treatment resistant cases.
Objectives
To describe a cohort of CRMO patients and character-
ize treatment effect.
Methods
Data from all patients diagnosed with CRMO from 2002
to 2011, at the east Danish specialized pediatric rheuma-
tology unit, were collected through review of medical
records.
The effect of treatment were evaluated by the clinical
symptoms, blood analysis and by Magnetic Resonance
Imagining (MRI).
Results
From January 2002 to December 2011, twenty-five chil-
dren under the age of 16 years were diagnosed with
CRMO. 16 females, 9 males. The most frequent foci
were in the tibia (8), femur (7), clavicle (7) and fibula
(4). 56% of the patients had unifocal affection and 24%
could be diagnosed with SAPHO syndrome.
Seven patients (28%) had sufficient effect of treatment
with NSAIDs.
Only three out of 18 patients treated with Methrotrex-
ate (MTX) had sufficient effect of the drug.
15 patients were treated with TNF-a inhibitors. 12
patients changed to a 2.line and three to a 3. line TNF-
a inhibitor, due to either insufficient effect or adverse
events.
The overall effect of TNF-a inhibitor were very good.
The effects of treatments are shown in Table 1.
Conclusion
The gender and age distribution of our patients resam-
ple that of the literature. In contrast we found a limited
amount of foci, 1,6/patient. A large number of our
patients developed SAPHO-syndrome. This could be
caused by selection bias, since we are a highly specia-
lized unit, with primarily more complicated patients
being referred.
MTX had a disappointing effect on our cohort, in
contrast to that of TNF-a inhibitors.
A treatment-resistant group of patients showed good
effect from TNF-a inhibitors, both clinical and on MRI.
In conclusion TNF-a inhibitors seem to be a relevant








Sufficient clinical effect of MTX (n:18) 3 17 %
Sufficient clinical effect of TNF-a (n:31) 18 58 %
Regression on MRI, MTX (n:9) 4 44 %
Regression on MRI, TNF-a (n:13) 11 84 %
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